ARF4 Antibody (Mouse mAb) [M2B13]

Application: Reactivity: Mouse, Rat, Human

Usage Information

Dilution
WB1:5000-1:50000 IHC1:1000-1:4000 IF1:400-1:1600 FCM1:5000

Application
WB, IHC, IF, FCM, ELISA

Reactivity
Mouse, Rat, Human

Source
Mouse Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW Observed MW
21 kDa 18 kDa
^*Why do the predicted and actual molecular weights differ? The following reasons may explain differences between the predicted and actual protein molecular weight. Post-translational modifications(e.g., phosphorylation, glycosylation); Splice variants and isoforms; Relative charge; Multimerization.

Datasheet & SDS

Biological Description

Specificity
ARF4 Antibody (Mouse mAb) [M2B13] detects endogenous levels of total ARF4 protein.

Clone
M2B13

Synonym(s)
ADP-ribosylation factor 4, ARF4, ARF2

Background
ARF4, also designated ARF2, belongs to the ADP-ribosylation factor family within the Ras superfamily of small GTPases and functions as a class II Arf, cycling between an inactive GDP-bound state and an active GTP-bound conformation that determines its membrane association and effector engagement. Activated, GTP-bound ARF4 associates with the trans-Golgi network, where it directly binds a specific ciliary-targeting sequence, the VxPx motif, present in the cytoplasmic C-terminal tail of the sensory receptor rhodopsin, and this direct receptor-GTPase interaction nucleates assembly of a defined ciliary membrane-targeting complex at the site where post-Golgi transport carriers are generated. This trafficking complex additionally incorporates the small GTPase Rab11, the Rab11/Arf effector FIP3, and the Arf GTPase-activating protein ASAP1, and ASAP1 functions as both an ARF4 GTPase-activating protein, driving GTP hydrolysis on ARF4, and as an ARF4 effector that regulates the budding of transport carriers from the trans-Golgi network, coupling ARF4 inactivation directly to vesicle scission rather than treating GTP hydrolysis as a purely terminal, complex-disassembling event. Genetic disruption of this GTPase cycle produces a defined trafficking defect: an ARF4 point mutant impaired specifically in ASAP1-mediated GTP hydrolysis causes aberrant rhodopsin trafficking together with cytoskeletal and morphological abnormalities that culminate in retinal degeneration in transgenic animals, directly linking the ARF4-ASAP1 GTP hydrolysis step to photoreceptor structural integrity rather than to rhodopsin transport alone. Because the VxPx motif recognized by ARF4 is present in other ciliary membrane proteins beyond rhodopsin, this ARF4-based targeting complex is understood to function as conserved machinery for selecting and packaging cargo destined for delivery to the primary cilium generally, extending ARF4's relevance beyond photoreceptor biology into ciliary trafficking pathways implicated across multiple human disorders involving primary cilia dysfunction. Upstream of cargo engagement, the Arf guanine nucleotide exchange factor GBF1 is positioned at trans-Golgi membranes through interaction with the small GTPase Rab6, where cargo binding together with ARF4 engagement of GBF1's regulatory DCB-HUS domain stimulates rapid accumulation of active, GTP-bound ARF4, establishing a positive feedback loop in which incoming cargo itself promotes the GTPase activation required for its own packaging into transport carriers. This cargo-stimulated activation mechanism, together with the downstream ASAP1-dependent hydrolysis step required for carrier budding, positions ARF4 as a defined checkpoint in cilium-directed membrane trafficking, with functional disruption at either step sufficient to produce sensory receptor mislocalization and degenerative retinal phenotypes.

Background

ARF4, also designated ARF2, belongs to the ADP-ribosylation factor family within the Ras superfamily of small GTPases and functions as a class II Arf, cycling between an inactive GDP-bound state and an active GTP-bound conformation that determines its membrane association and effector engagement. Activated, GTP-bound ARF4 associates with the trans-Golgi network, where it directly binds a specific ciliary-targeting sequence, the VxPx motif, present in the cytoplasmic C-terminal tail of the sensory receptor rhodopsin, and this direct receptor-GTPase interaction nucleates assembly of a defined ciliary membrane-targeting complex at the site where post-Golgi transport carriers are generated. This trafficking complex additionally incorporates the small GTPase Rab11, the Rab11/Arf effector FIP3, and the Arf GTPase-activating protein ASAP1, and ASAP1 functions as both an ARF4 GTPase-activating protein, driving GTP hydrolysis on ARF4, and as an ARF4 effector that regulates the budding of transport carriers from the trans-Golgi network, coupling ARF4 inactivation directly to vesicle scission rather than treating GTP hydrolysis as a purely terminal, complex-disassembling event. Genetic disruption of this GTPase cycle produces a defined trafficking defect: an ARF4 point mutant impaired specifically in ASAP1-mediated GTP hydrolysis causes aberrant rhodopsin trafficking together with cytoskeletal and morphological abnormalities that culminate in retinal degeneration in transgenic animals, directly linking the ARF4-ASAP1 GTP hydrolysis step to photoreceptor structural integrity rather than to rhodopsin transport alone. Because the VxPx motif recognized by ARF4 is present in other ciliary membrane proteins beyond rhodopsin, this ARF4-based targeting complex is understood to function as conserved machinery for selecting and packaging cargo destined for delivery to the primary cilium generally, extending ARF4's relevance beyond photoreceptor biology into ciliary trafficking pathways implicated across multiple human disorders involving primary cilia dysfunction. Upstream of cargo engagement, the Arf guanine nucleotide exchange factor GBF1 is positioned at trans-Golgi membranes through interaction with the small GTPase Rab6, where cargo binding together with ARF4 engagement of GBF1's regulatory DCB-HUS domain stimulates rapid accumulation of active, GTP-bound ARF4, establishing a positive feedback loop in which incoming cargo itself promotes the GTPase activation required for its own packaging into transport carriers. This cargo-stimulated activation mechanism, together with the downstream ASAP1-dependent hydrolysis step required for carrier budding, positions ARF4 as a defined checkpoint in cilium-directed membrane trafficking, with functional disruption at either step sufficient to produce sensory receptor mislocalization and degenerative retinal phenotypes.

References
https://pubmed.ncbi.nlm.nih.gov/19153612/ https://pubmed.ncbi.nlm.nih.gov/29025970/

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%